A carregar...
Cost‐effectiveness and financial risks associated with immune checkpoint inhibitor therapy
The reimbursement of immune checkpoint inhibitors is challenging. Funding these technologies involves the careful balance between awarding innovation and ensuring affordability as increases in drug spending compete directly with other health care and social expenditure. This narrative review examine...
Na minha lista:
| Publicado no: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7444763/ https://ncbi.nlm.nih.gov/pubmed/32358803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14337 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|